Patienter med nedsat leverfunktion har muligvis en øget risiko for toksicitet, især i form af myelosuppression, og sådanne patienter bør overvåges nøje for udvikling af svær myelosuppression.
Patients with hepatic impairment may be at increased risk of toxicity, particularly from myelosuppression, and such patients should be closely monitored for development of profound myelosuppression.